Skip to content

Clinical trial of sphenopalatine ganglion pulsed radiofrequency on drug resistant allergic rhinitis

Clinical trial of sphenopalatine ganglion pulsed radiofrequency on drug resistant allergic rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058012
Enrollment
Unknown
Registered
2022-03-26
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

study group :pulsed radiofrequency

Sponsors

Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1)Compliance with the diagnostic criteria in the ' Diagnosis and Guidelines for Allergic Rhinitis ' developed by the Department of Otolaryngology Head and Neck Surgery of the Chinese Medical Association in 2016; 2)Criteria for drug-resistant allergic rhinitis : patients whose symptoms could not be controlled after 4 - week treatment with nasal spray hormone combined with antihistamine drugs; 3)Tolerance of Pulsed Radiofrequency Therapy for Sphenopalatine Ganglion; 4)ASA?-?; 5)Age 18-60; 6)Patients signed informed consent.

Exclusion criteria

Exclusion criteria: 1 ) Pregnant or lactating, menstrual women, women planning to become pregnant within 3 months ; 2 ) Patients who received other treatment or oral, topical glucocorticoid, antihistamine and immunotherapy within four weeks before treatment ; 3 ) Congenital nasal deformity, sinus disease, severe nasal septum deviation and nasal polyps ; 4 ) combined with other refractory diseases such as specific dermatitis or a history of parasitic infection ; 5 ) patients with severe cardiovascular and cerebrovascular diseases, liver and kidney blood system diseases or malignant tumors, mental illness, diabetes, patients with bleeding tendency ; 6 ) Patients with pacemaker, defibrillator, artificial joint, contraceptive ring, etc. Because magnetic resonance imaging is performed in a narrow barrel environment, subjects with claustrophobia cannot participate in the test ; 7 ) Patients who failed to sign informed consent.

Design outcomes

Primary

MeasureTime frame
TNSS;signs indexes;RQLQ;fMRI;

Secondary

MeasureTime frame
IgE;substance-P;

Countries

China

Contacts

Public ContactXuebi Tian
Tianxb@hust.edu.cn17371266823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026